MAP2K7 and neoplasm: The BRD4 bromodomain inhibitor JQ1 blocks the MEK-inhibitor-induced enhancer landscape remodeling, and a combination of JQ1 with the MEK inhibitor trametinib synergistically suppressed tumor growth in vitro and in vivo in orthotopic xenografts.